Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
* Swiss contract drug manufacturer Lonza rises 2.2% after setting new mid-term targets and confirming its 2026 outlook * Lonza targets 10% to 13% organic sales growth and a core EBITDA margin in the high thirties in the medium term * Vontobel says the updated targets imply some upside to its estimates and sees free cas
Oct 14 (Reuters) — Swiss contract drug manufacturer Lonza set new mid-term targets and confirmed its 2026 outlook on Wednesday ahead of its capital markets day, while saying third-quarter performance was in line with expectations across its business areas. Lonza is seeking to become a pure-play drug manufacturer once i
Lonza targets average organic sales growth in the low teens over time at constant exchange rates and aims to accelerate core EBITDA margin expansion, targeting a margin in the high thirties over the medium term.
Lonza now aims for a core EBITDA margin in the high thirties over the medium term.